Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.
2.

Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer.

Patel SB, Gill D, Garrido-Laguna I.

Onco Targets Ther. 2015 Dec 30;9:75-86. doi: 10.2147/OTT.S68558. eCollection 2016. Review.

3.

Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?

Osumi H, Shinozaki E, Suenaga M, Kumekawa Y, Ogura M, Ozaka M, Matsusaka S, Chin K, Yamamoto N, Mizunuma N.

BMC Cancer. 2015 Oct 21;15:760. doi: 10.1186/s12885-015-1751-6.

4.

Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective technique.

Kriegsmann M, Arens N, Endris V, Weichert W, Kriegsmann J.

Diagn Pathol. 2015 Jul 30;10:132. doi: 10.1186/s13000-015-0364-3.

5.

Clinical next generation sequencing to identify actionable aberrations in a phase I program.

Boland GM, Piha-Paul SA, Subbiah V, Routbort M, Herbrich SM, Baggerly K, Patel KP, Brusco L, Horombe C, Naing A, Fu S, Hong DS, Janku F, Johnson A, Broaddus R, Luthra R, Shaw K, Mendelsohn J, Mills GB, Meric-Bernstam F.

Oncotarget. 2015 Aug 21;6(24):20099-110.

6.

CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.

Oberst MD, Fuhrmann S, Mulgrew K, Amann M, Cheng L, Lutterbuese P, Richman L, Coats S, Baeuerle PA, Hammond SA.

MAbs. 2014;6(6):1571-84. doi: 10.4161/19420862.2014.975660.

7.

Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.

Kleist B, Kempa M, Novy M, Oberkanins C, Xu L, Li G, Loland C, Poetsch M.

Int J Clin Exp Pathol. 2014 Aug 15;7(9):5927-39. eCollection 2014.

8.

Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer.

Luo HY, Xu RH.

World J Gastroenterol. 2014 Apr 14;20(14):3858-74. doi: 10.3748/wjg.v20.i14.3858. Review.

9.

Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer.

Coppedè F, Lopomo A, Spisni R, Migliore L.

World J Gastroenterol. 2014 Jan 28;20(4):943-56. doi: 10.3748/wjg.v20.i4.943. Review.

10.

Spectrum of EGFR gene copy number changes and KRAS gene mutation status in Korean triple negative breast cancer patients.

Kim Y, Kim J, Lee HD, Jeong J, Lee W, Lee KA.

PLoS One. 2013 Oct 30;8(10):e79014. doi: 10.1371/journal.pone.0079014. eCollection 2013. Erratum in: PLoS One. 2014;9(11):e114660.

11.

Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients.

Guinney J, Ferté C, Dry J, McEwen R, Manceau G, Kao KJ, Chang KM, Bendtsen C, Hudson K, Huang E, Dougherty B, Ducreux M, Soria JC, Friend S, Derry J, Laurent-Puig P.

Clin Cancer Res. 2014 Jan 1;20(1):265-272. doi: 10.1158/1078-0432.CCR-13-1943. Epub 2013 Oct 29.

12.

The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers.

Glynne-Jones R, Hadaki M, Harrison M.

J Gastrointest Oncol. 2013 Sep;4(3):264-84. doi: 10.3978/j.issn.2078-6891.2013.037.

13.

Expression of E-cadherin and KRAS mutation may serve as biomarkers of cetuximab-based therapy in metastatic colorectal cancer.

Nakamoto K, Nagahara H, Maeda K, Noda E, Inoue T, Yashiro M, Nishiguchi Y, Ohira M, Hirakawa K.

Oncol Lett. 2013 Apr;5(4):1295-1300. Epub 2013 Feb 8.

14.

KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2010;10(25):1-49. Epub 2010 Dec 1.

15.

The pattern of epidermal growth factor receptor variation with disease progression and aggressiveness in colorectal cancer depends on tumor location.

Papagiorgis PC, Zizi AE, Tseleni S, Oikonomakis IN, Nikiteas NI.

Oncol Lett. 2012 May;3(5):1129-1135. Epub 2012 Feb 28.

16.

Comparative genomic analysis of primary versus metastatic colorectal carcinomas.

Vakiani E, Janakiraman M, Shen R, Sinha R, Zeng Z, Shia J, Cercek A, Kemeny N, D'Angelica M, Viale A, Heguy A, Paty P, Chan TA, Saltz LB, Weiser M, Solit DB.

J Clin Oncol. 2012 Aug 20;30(24):2956-62. doi: 10.1200/JCO.2011.38.2994. Epub 2012 Jun 4.

17.

p53 modulates acquired resistance to EGFR inhibitors and radiation.

Huang S, Benavente S, Armstrong EA, Li C, Wheeler DL, Harari PM.

Cancer Res. 2011 Nov 15;71(22):7071-9. doi: 10.1158/0008-5472.CAN-11-0128. Epub 2011 Nov 8.

18.

Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer.

Loupakis F, Cremolini C, Fontanini G, Stasi I, Salvatore L, Falcone A.

Ther Adv Med Oncol. 2009 Nov;1(3):167-81. doi: 10.1177/1758834009348984.

19.

Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells.

Rigatti MJ, Verma R, Belinsky GS, Rosenberg DW, Giardina C.

Mol Carcinog. 2012 May;51(5):363-78. doi: 10.1002/mc.20795. Epub 2011 May 6.

20.

Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer.

Kelley RK, Van Bebber SL, Phillips KA, Venook AP.

J Natl Compr Canc Netw. 2011 Jan;9(1):13-25. Review.

Supplemental Content

Support Center